Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Mouse (Murine) MYL2 Antibodies:
anti-Human MYL2 Antibodies:
anti-Rat (Rattus) MYL2 Antibodies:
Go to our pre-filtered search.
Human Monoclonal MYL2 Primary Antibody for ELISA, FACS - ABIN450002
Samwer, Dehne, Spira, Kollmar, Gerlich, Urlaub, Görlich: The nuclear F-actin interactome of Xenopus oocytes reveals an actin-bundling kinesin that is essential for meiotic cytokinesis. in The EMBO journal 2013
Show all 3 Pubmed References
Human Monoclonal MYL2 Primary Antibody for ELISA, WB - ABIN969302
Sachdev, Raychowdhury, Sarkar: Human fast skeletal myosin light chain 2 cDNA: isolation, tissue specific expression of the single copy gene, comparative sequence analysis of isoforms and evolutionary relationships. in DNA sequence : the journal of DNA sequencing and mapping 2004
Show all 2 Pubmed References
Human Monoclonal MYL2 Primary Antibody for IF, IP - ABIN561897
Gannon, Doran, Kirwan, Ohlendieck: Drastic increase of myosin light chain MLC-2 in senescent skeletal muscle indicates fast-to-slow fibre transition in sarcopenia of old age. in European journal of cell biology 2009
Human Polyclonal MYL2 Primary Antibody for IHC, IHC (p) - ABIN4337526
He, Tian, Zhang, Hu, Huang, Zhang, Wang, Zhou: BAF200 is required for heart morphogenesis and coronary artery development. in PLoS ONE 2014
Human Monoclonal MYL2 Primary Antibody for ELISA, WB - ABIN966625
Ueda, Murata-Hori, Tatsuka, Hosoya: Rho-kinase contributes to diphosphorylation of myosin II regulatory light chain in nonmuscle cells. in Oncogene 2002
Show all 2 Pubmed References
Human Polyclonal MYL2 Primary Antibody for IHC - ABIN966635
Janiak, Zemskov, Belkin: Cell surface transglutaminase promotes RhoA activation via integrin clustering and suppression of the Src-p190RhoGAP signaling pathway. in Molecular biology of the cell 2006
Human Polyclonal MYL2 Primary Antibody for IHC, WB - ABIN1742562
Yeo, Ting, Brena, Koh, Chen, Toh, Lim, Oh, Lee: Genome-Wide Transcriptome and Binding Sites Analyses Identify Early FOX Expressions for Enhancing Cardiomyogenesis Efficiency of hESC Cultures. in Scientific reports 2016
transgenic mouse models of hypertrophic cardiomyopathy may be caused by mutations in myosin regulatory light chain
MLC2 phosphorylation regulates actin-based cytokinesis in mouse oocytes, and this regulation may be mediated via a RhoA-MLC2-actin pathway.
Treatment of mice with an AT1R (show AGTRAP Antibodies) biased ligand, acting via beta-arrestin signalling, is able to induce an increase in cardiac contractility associated with an increase in ventricular myosin light chain-2 (show MYL12B Antibodies) phosphorylation
Hypertrophic cardiomyopathy associated Lys104Glu mutation in the myosin regulatory light chain causes diastolic disturbance in mice.
Mammalian target of rapamycin (mTOR (show FRAP1 Antibodies)) inhibition with rapamycin improves cardiac function in type 2 diabetic mice: potential role of attenuated oxidative stress and altered contractile protein (show TNNT2 Antibodies) expression.
Data indicate that NRG-1beta up-regulated the gene expressions of Nkx2.5 (show NKX2-5 Antibodies), GATA4 (show GATA4 Antibodies), alpha-actin (show ACTA2 Antibodies), MLC-2v, and ANF (show HESX1 Antibodies) in a time-dependent regulation of ErbB (show EGFR Antibodies)/ERK1/2 (show MAPK1/3 Antibodies) pathways.
Results indicated that sine oculis homeobox (show PRRX1 Antibodies) 1 (Six1 (show SIX1 Antibodies)) overexpression could significantly promote the expression of fast-type muscle genes Atp2a1 (show ATP2A1 Antibodies), Srl (show SRL Antibodies), and Mylpf (show MYLPF Antibodies).
High resolution characterization of myosin IIC protein tailpiece and its effect on filament assembly
Accelerated cMLCK protein turnover by the ubiquitin-proteasome system underlies the transition from compensated hypertrophy to decompensated heart failure as a result of reduced phosphorylation of MLC2v.
Results show that the binding force between selenium and cardiac myosin (CM), which consists of two heavy chains (MHC) and two pairs of light chains: MLC1 and MLC2, was 100 times stronger than that of daunorubicin (DNR) and CM.
The results show that the MYL2 mutation c.64G > A on its own is incapable of triggering clinical HCM in most carriers. However, the presence of an additional risk factor for hypertrophy, particularly hypertension, adds to the development of HCM.
Our study provides the first evidence that miR (show MLXIP Antibodies)-223 can regulate pulmonary artery smooth muscle cells proliferation, migration, and actomyosin reorganization through its novel targets, RhoB and MLC2 (show MYL9 Antibodies), resulting in vascular remodeling and the development of pulmonary arterial hypertension.
NKX2-5 (show NKX2-5 Antibodies) and MLC2v double-positive cells possess ventricular-like properties. The results demonstrate that the NKX2-5 (show NKX2-5 Antibodies)(eGFP/w) and MLC2v(mCherry/w) hPSCs provide a powerful model system to capture region-specific cardiac differentiation from early to late stages. Our study would facilitate subtype-specific cardiac development and functional analysis using the hPSC-derived sources.
This exome-wide association study indicated that C12orf51 rs11066280, MYL2 rs12229654, and ALDH2 (show ALDH2 Antibodies) rs671 polymorphisms are linked to blood Pb levels in the Korean population.
differential regulation of PKA and cell stiffness in unconfined versus confined cells is abrogated by dual, but not individual, inhibition of Piezo1 and myosin II.
Mutation in myosin regulatory light chain gene is associated with defective myosin motor function that ultimately result in pathological hypertrophic remodeling.
Lipolysis-stimulated lipoprotein receptors (LSRs) localized to bicellular junctions in association with myosin regulatory light chain 2 (MRLC2 (show MYL12B Antibodies)) at low cell densities and to tricellular contacts when myosin phosphatase target subunit 1 (MYPT1 (show PPP1R12A Antibodies)) localized to the bicellular regions.
Structural dynamics-based approach reveals that the E56G mutation in human ventricular essential light chain affects the structure of the actin-myosin complex in the presence of ATP. The mutation increases the population in the S structural state (increasing the duty ratio), and changes the structure of the W state, so that it more closely resembles the S state.
Two siblings with hypertrophic cardiomyopathy had the pathogenic variant p.Ala13Thr variant in MYL2.
the MYL2 gene on chromosome 12 is associated with serum HDL (show HSD11B1 Antibodies)-C levels in Korean men. The association was much stronger in male obese subjects and smokers than that in leaner (show CACNA1A Antibodies) nonsmoking male subjects.
Thus gene encodes the regulatory light chain associated with cardiac myosin beta (or slow) heavy chain. Ca+ triggers the phosphorylation of regulatory light chain that in turn triggers contraction. Mutations in this gene are associated with mid-left ventricular chamber type hypertrophic cardiomyopathy.
, fast skeletal myosin light chain 2
, myosin light chain 2
, myosin regulatory light chain 2, skeletal muscle isoform
, RLC of myosin
, cardiac ventricular myosin light chain 2
, myosin regulatory light chain 2, ventricular/cardiac muscle isoform
, myosin, light polypeptide 2, regulatory, cardiac, slow
, regulatory light chain of myosin
, slow cardiac myosin regulatory light chain 2
, cardiac myosin light chain-2
, isoform L20-A
, light polypeptide 9
, myosin regulatory light chain 2, smooth muscle major isoform
, myosin regulatory light polypeptide 9
, myosin, light polypeptide 9, regulatory
, smooth muscle major isoform
, myosin light chain 2v
, myosin light chain, phosphorylatable, cardiac ventricles
, ventricular myosin regulatory light chain